Aviva Atri-Schuller

Dr. Aviva Atri-Schuller


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAviva Atri-Schuller
Aviva Atri-Schuller
HAHassan Mohammed Abushukair
Hassan Mohammed Abushukair
LCLudimila Cavalcante
Ludimila Cavalcante
SHStijn Hentzen
Stijn Hentzen
ASAzhar Saeed
Azhar Saeed
ASAnwaar Saeed
Anwaar Saeed
Although most people are infected with Epstein-Barr Virus (EBV) during their lifetime, only a minority of them develop an EBV-associated malignancy. EBV acts in both direct and indirect ways to transform infected cells into tumor cells. There are multiple ways in which the EBV, host, and tumor environment interact to promote malignant transformation. This paper focuses on some of the mechanisms that EBV uses to transform the tumor microenvironment (TME) of EBV-associated gastric cancer (EBVaGC) for its benefit, including overexpression of Indoleamine 2,3-Dioxygenase 1 (IDO1), synergism between H. pylori and EBV co-infection, and M1 to M2 switch. In this review, we expand on different modalities and combinatorial approaches to therapeutically target this mechanism.

7 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAviva Atri-Schuller
Aviva Atri-Schuller
HAHassan Mohammed Abushukair
Hassan Mohammed Abushukair
LCLudimila Cavalcante
Ludimila Cavalcante
SHStijn Hentzen
Stijn Hentzen
ASAzhar Saeed
Azhar Saeed
ASAnwaar Saeed
Anwaar Saeed
Although most people are infected with Epstein-Barr Virus (EBV) during their lifetime, only a minority of them develop an EBV-associated malignancy. EBV acts in both direct and indirect ways to transform infected cells into tumor cells. There are multiple ways in which the EBV, host, and tumor environment interact to promote malignant transformation. This paper focuses on some of the mechanisms that EBV uses to transform the tumor microenvironment (TME) of EBV-associated gastric cancer (EBVaGC) for its benefit, including overexpression of IDO1, synergism between H pylori and EBV coinfection, and M1 to M2 switch. In this review, we expand on different modalities and combinatorial approaches to therapeutically target this mechanism.